The 'King Kong' of drugs could be approved in the US within months, its manufacturer says.In a recent trial, patients who received a weekly 15milligram (mg) shot of Mounjaro lost 15.7 percent of their body weight over 72 weeks on average. For comparison, those in the placebo group lost just 3.3 percent of their weight over the same period.Eli Lilly, which manufactures the drug, said the results paved the way for it to be approved to treat weight loss. Tirzepatide, the active drug behind Mounjaro, was approved for patients with type 2 diabetes last year.
Load More
Load More